Investigating human disease using stem cell models

Nature Reviews Genetics

Volumn 15, Issue 9, 2014, Pages 625-639

  Sterneckert, Jared L ^a   Reinhardt, Peter ^a   Schöler, Hans R ^a  

^a MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIN A; NEW DRUG; PROGERIN; UNCLASSIFIED DRUG;

ADULT STEM CELL; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CARDIOTOXICITY; CELL AGING; CELL DIFFERENTIATION; CELL RENEWAL; COCULTURE; DEGENERATIVE DISEASE; DISEASE MODEL; DNA MODIFICATION; DRUG RESPONSE; DRUG SCREENING; DRUG TARGETING; EMBRYONIC STEM CELL; EXCITOTOXICITY; FRAGILE X SYNDROME; GENE MUTATION; GENE TARGETING; GENETIC SCREENING; GENETIC VARIABILITY; GENOME EDITING; HEART DISEASE; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL CULTURE; HUNTINGTON CHOREA; IN VITRO STUDY; LIVER DISEASE; LONG QT SYNDROME; MACHADO JOSEPH DISEASE; MONOGENIC DISORDER; NEURAL STEM CELL; NONHUMAN; OXIDATIVE STRESS; PANCREAS ADENOCARCINOMA; PARKINSON DISEASE; PATHOGENESIS; PLURIPOTENT STEM CELL; PREIMPLANTATION GENETIC DIAGNOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT INTERVAL; REVIEW; STEM CELL; STEM CELL CULTURE; TOXICITY TESTING; VIRUS INFECTION;

CELL DIFFERENTIATION; DISEASE; GENOME, HUMAN; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MUTATION; RNA EDITING;

EID: 84906319803     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg3764     Document Type: Review

References (140)

1. Schwartz, P. H. et al. Neural progenitor cells from an adult patient with fragile X syndrome. BMC Med. Genet. 6, 2 (2005).
2. Haidet-Phillips, A. M. et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nature Biotech. 29, 824-828 (2011).
3. Eiges, R. et al. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 1, 568-577 (2007). (Pubitemid 350079966)
4. Niclis, J. C. et al. Characterization of forebrain neurons derived from late-onset Huntington's disease human embryonic stem cell lines. Front. Cell Neurosci. 7, 37 (2013).
5. Biancotti, J. C. et al. Human embryonic stem cells as models for aneuploid chromosomal syndromes. Stem Cells 28, 1530-1540 (2010).
6. Mateizel, I. et al. Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Hum. Reprod. 21, 503-511 (2006). (Pubitemid 43159929)
7. Marchetto, M. C. et al. Non-cell-autonomous effect of human SOD1G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell 3, 649-657 (2008).
8. Di Giorgio, F. P., Boulting, G. L., Bobrowicz, S. & Eggan, K. C. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 3, 637-648 (2008).
9. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006). (Pubitemid 44233629)
10. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007). (Pubitemid 350138099)
11. Ebert, A. D. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277-280 (2009).
12. HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11, 264-278 (2012).
13. Zhang, N., An, M. C., Montoro, D. & Ellerby, L. M. Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Curr. 2, RRN1193 (2010).
14. Chae, J. I. et al. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem. J. 446, 359-371 (2012).
15. Camnasio, S. et al. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol. Dis. 46, 41-51 (2012).
16. Jeon, I. et al. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells 30, 2054-2062 (2012).
17. Moretti, A. et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 363, 1397-1409 (2010).
18. Itzhaki, I. et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471, 225-229 (2011).
19. Zhang, S. et al. Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Hum. Mol. Genet. 20, 3176-3187 (2011).
20. Eggenschwiler, R. et al. Sustained knockdown of a disease-causing gene in patient-specific induced pluripotent stem cells using lentiviral vector-based gene therapy. Stem Cells Transl. Med. 2, 641-654 (2013).
21. Ye, Z. et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 114, 5473-5480 (2009).
22. Kim, J. et al. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep. 3, 2088-2099 (2013).
23. Li, X. et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 30, 1788-1797 (2010).
24. Healy, D. G. et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 7, 583-590 (2008).
25. Trinh, J. et al. A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. Neurobiol. Aging 35, 1125-1131 (2013).
26. Nguyen, H. N. et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8, 267-280 (2011).
27. Sanchez-Danes, A. et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med. 4, 380-395 (2012).
28. Kondo, T. et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell 12, 487-496 (2013).
29. Reinhardt, P. et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 12, 354-367 (2013).
30. Liu, G. H. et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491, 603-607 (2012).
31. Miller, J. D. et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13, 691-705 (2013).
32. Dekker, P. et al. Chronic inhibition of the respiratory chain in human fibroblast cultures: differential responses related to subject chronological and biological age. J. Gerontol. A Biol. Sci. Med. Sci. 67, 456-464 (2012).
33. Noppe, G. et al. Rapid flow cytometric method for measuring senescence associated β-galactosidase activity in human fibroblasts. Cytometry A 75, 910-916 (2009).
34. Koch, P. et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 480, 543-546 (2011).
35. Yusa, K. et al. Targeted gene correction of ?1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478, 391-394 (2011).
36. Choi, S. M. et al. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology 57, 2458-2468 (2013).
37. Zou, J., Mali, P., Huang, X., Dowey, S. N. & Cheng, L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118, 4599-4608 (2011).
38. Wang, Y. et al. Genetic correction of beta-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice. Cell Res. 22, 637-648 (2012).
39. Fong, H. et al. Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Rep. 1, 226-234 (2013).
40. An, M. C. et al. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11, 253-263 (2012).
41. Corti, S. et al. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci. Transl Med. 4, 165ra162 (2012).
42. ISIS Pharmaceuticals. Press release: Data from ISIS-SMN Rx Phase 1 study in children with spinal muscular atrophy presented at the American Academy of Neurology Meeting [online], http://ir.isispharm.com/ phoenix.zhtml?c= 222170&p=irol-newsArticle&ID=1798657 (2014).
43. Ryan, S. D. et al. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1? transcription. Cell 155, 1351-1364 (2013).
44. Ding, Q. et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 12, 238-251 (2013).
45. Roelandt, P. et al. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J. Hepatol 57, 246-251 (2012).
46. Wu, X. et al. Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog. 8, e1002617 (2012).
47. Yoshida, T. et al. Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection. Biochem. Biophys. Res. Commun. 416, 119-124 (2011).
48. Schwartz, R. E. et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc. Natl Acad. Sci. USA 109, 2544-2548 (2012).
49. Penkert, R. R. & Kalejta, R. F. Human embryonic stem cell lines model experimental human cytomegalovirus latency. MBio 4, e00298-00213 (2013).
50. D'Aiuto, L. et al. Human induced pluripotent stem cell-derived models to investigate human cytomegalovirus infection in neural cells. PLoS ONE 7, e49700 (2012).
51. Hoing, S. et al. Discovery of inhibitors of microglial neurotoxicity acting through multiple mechanisms using a stem-cell-based phenotypic assay. Cell Stem Cell 11, 620-632 (2012).
52. Yang, Y. M. et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 12, 713-726 (2013).
53. Braam, S. R. et al. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 4, 107-116 (2010).
54. Liang, P. et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127, 1677-1691 (2013).
55. Poduri, A., Evrony, G. D., Cai, X. & Walsh, C. A. Somatic mutation, genomic variation, and neurological disease. Science 341, 1237758 (2013).
56. Gore, A. et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 471, 63-67 (2011).
57. Theka, I. et al. Rapid generation of functional dopaminergic neurons from human induced pluripotent stem cells through a single-step procedure using cell lineage transcription factors. Stem Cells Transl. Med. 2, 473-479 (2013).
58. Han, D. W. et al. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell 10, 465-472 (2012).
59. Zwaka, T. P. & Thomson, J. A. Homologous recombination in human embryonic stem cells. Nature Biotech. 21, 319-321 (2003). (Pubitemid 36314818)
60. Heaney, J. D., Rettew, A. N. & Bronson, S. K. Tissue-specific expression of a BAC transgene targeted to the Hprt locus in mouse embryonic stem cells. Genomics 83, 1072-1082 (2004). (Pubitemid 38726055)
61. Xue, H. et al. A targeted neuroglial reporter line generated by homologous recombination in human embryonic stem cells. Stem Cells 27, 1836-1846 (2009).
62. Song, H., Chung, S. K. & Xu, Y. Modeling disease in human ESCs using an efficient BAC-based homologous recombination system. Cell Stem Cell 6, 80-89 (2010).
63. Goulburn, A. L. et al. A targeted NKX2.1 human embryonic stem cell reporter line enables identification of human basal forebrain derivatives. Stem Cells 29, 462-473 (2011).
64. Aizawa, E. et al. Efficient and accurate homologous recombination in hESCs and hiPSCs using helper-dependent adenoviral vectors. Mol. Ther. 20, 424-431 (2012).
65. Hockemeyer, D. et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nature Biotech. 27, 851-857 (2009).
66. Hockemeyer, D. et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nature Biotech. 29, 731-734 (2011).
67. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotech. 31, 822-826 (2013).
68. Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380-1389 (2013).
69. Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotech. 31, 833-838 (2013).
70. Ding, Q. et al. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 12, 393-394 (2013).
71. Kelly, R. D., Mahmud, A., McKenzie, M., Trounce, I. A. & St John, J. C. Mitochondrial DNA copy number is regulated in a tissue specific manner by DNA methylation of the nuclear-encoded DNA polymerase gamma A. Nucleic Acids Res. 40, 10124-10138 (2012).
72. Van Blerkom, J., Sinclair, J. & Davis, P. Mitochondrial transfer between oocytes: potential applications of mitochondrial donation and the issue of heteroplasmy. Hum. Reprod. 13, 2857-2868 (1998). (Pubitemid 28482742)
73. Brenner, C. A., Barritt, J. A., Willadsen, S. & Cohen, J. Mitochondrial DNA heteroplasmy after human ooplasmic transplantation. Fertil. Steril. 74, 573-578 (2000).
74. Tachibana, M. et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 153, 1228-1238 (2013).
75. Tachibana, M. et al. Towards germline gene therapy of inherited mitochondrial diseases. Nature 493, 627-631 (2013).
76. Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480, 547-551 (2011).
77. Reinhardt, P. et al. Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling. PLoS ONE 8, e59252 (2013).
78. Koch, P., Opitz, T., Steinbeck, J. A., Ladewig, J. & Brustle, O. A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration. Proc. Natl Acad. Sci. USA 106, 3225-3230 (2009).
79. Li, W. et al. Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. Proc. Natl Acad. Sci. USA 108, 8299-8304 (2011).
80. Cao, N. et al. Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions. Cell Res. 23, 1119-1132 (2013).
81. Cheng, X. et al. Self-renewing endodermal progenitor lines generated from human pluripotent stem cells. Cell Stem Cell 10, 371-384 (2012).
82. Hannan, N. R. et al. Generation of multipotent foregut stem cells from human pluripotent stem cells. Stem Cell Rep. 1, 293-306 (2013).
83. Mummery, C. L. et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ. Res. 111, 344-358 (2012).
84. Takebe, T. et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499, 481-484 (2013).
85. Lancaster, M. A. et al. Cerebral organoids model human brain development and microcephaly. Nature 501, 373-379 (2013).
86. Eiraku, M. et al. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature 472, 51-56 (2011).
87. Nakano, T. et al. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell 10, 771-785 (2012).
88. Andr?e, B., Bor, A., Haverich, A. & Hilfiker, A. Small intestinal submucosa segments as matrix for tissue engineering: review. Tissue Eng. Part B Rev. 19, 279-291 (2013).
89. Bhise, N. S. et al. Organ-on-a-chip platforms for studying drug delivery systems. J. Control Release http://dx.doi.org/10.1016/j.jconrel.2014.05.004 (2014).
90. Botta-Orfila, T. et al. Age at onset in LRRK2-associated PD is modified by SNCA variants. J. Mol. Neurosci. 48, 245-247 (2012).
91. Rashid, S. T. et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J. Clin. Invest. 120, 3127-3136 (2010).
92. Almeida, S. et al. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep. 2, 789-798 (2012).
93. Sareen, D. et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl Med. 5, 208ra149 (2013).
94. Almeida, S. et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 126, 385-399 (2013).
95. Donnelly, C. J. et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415-428 (2013).
96. Chen, H. et al. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell 14, 796-809 (2014).
97. Kiskinis, E. et al. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell 14, 781-795 (2014).
98. Wainger, B. J. et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 7, 1-11 (2014).
99. Egawa, N. et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl Med. 4, 145ra104 (2012).
100. Bilican, B. et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl Acad. Sci. USA 109, 5803-5808 (2012).
101. Serio, A. et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc. Natl Acad. Sci. USA 110, 4697-4702 (2013).
102. Israel, M. A. et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482, 216-220 (2012).
103. Mertens, J. et al. APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based γ-secretase modulation. Stem Cell Rep. 1, 491-498 (2013).
104. Yagi, T. et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet. 20, 4530-4539 (2011).
105. Shi, Y. et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl Med. 4, 124ra29 (2012).
106. Jiang, Y. et al. Derivation and functional analysis of patient-specific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease. Stem Cells 30, 599-611 (2012).
107. Novak, A. et al. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation. J. Cell. Mol. Med. 16, 468-482 (2012).
108. Fatima, A. et al. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol. Biochem. 28, 579-592 (2011).
109. Kujala, K. et al. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations. PLoS ONE 7, e44660 (2012).
110. 2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. Cell Calcium 54, 57-70 (2013).
111. Jung, C. B. et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol. Med. 4, 180-191 (2012).
112. Sheridan, S. D. et al. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS ONE 6, e26203 (2011).
113. Matsa, E. et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur. Heart J. 32, 952-962 (2011).
114. Lahti, A. L. et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis. Model. Mech. 5, 220-230 (2012).
115. Bellin, M. et al. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J. 32, 3161-3175 (2013).
116. Egashira, T. et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc. Res. 95, 419-429 (2012).
117. Terrenoire, C. et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J. Gen. Physiol. 141, 61-72 (2013).
118. Davis, R. P. et al. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 125, 3079-3091 (2012).
119. Ma, D. et al. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. Int. J. Cardiol 168, 5277-5286 (2013).
120. Quarto, N. et al. Skeletogenic phenotype of human Marfan embryonic stem cells faithfully phenocopied by patient-specific induced-pluripotent stem cells. Proc. Natl Acad. Sci. USA 109, 215-220 (2012).
121. Cooper, O. et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci. Transl Med. 4, 141ra90 (2012).
122. Orenstein, S. J. et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nature Neurosci. 16, 394-406 (2013).
123. Sanders, L. H. et al. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol. Dis. 62, 381-386 (2014).
124. Jiang, H. et al. Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nature Commun. 3, 668 (2012).
125. Imaizumi, Y. et al. Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol. Brain 5, 35 (2012).
126. Seibler, P. et al. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J. Neurosci. 31, 5970-5976 (2011).
127. Byers, B. et al. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate ?-synuclein and are susceptible to oxidative stress. PLoS ONE 6, e26159 (2011).
128. Yagi, T. et al. Establishment of induced pluripotent stem cells from centenarians for neurodegenerative disease research. PLoS ONE 7, e41572 (2012).
129. Huang, H. P. et al. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum. Mol. Genet. 20, 4851-4864 (2011).
130. Suzuki, T. et al. Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis. Am. J. Respir. Crit. Care Med. 189, 183-193 (2014).
131. Lachmann, N. et al. Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 189, 167-182 (2014).
132. Ananiev, G., Williams, E. C., Li, H. & Chang, Q. Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as in vitro disease model. PLoS ONE 6, e25255 (2011).
133. Cheung, A. Y. et al. Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum. Mol. Genet. 20, 2103-2115 (2011).
134. Kim, K. Y., Hysolli, E. & Park, I. H. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc. Natl Acad. Sci. USA 108, 14169-14174 (2011).
135. Brennand, K. J. et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221-225 (2011).
136. Sareen, D. et al. Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PLoS ONE 7, e39113 (2012).
137. Chang, T. et al. Brief report: phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. Stem Cells 29, 2090-2093 (2011).
138. Pasca, S. P. et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nature Med. 17, 1657-1662 (2011).
139. Yazawa, M. et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471, 230-234 (2011).
140. Krey, J. F. et al. Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons. Nature Neurosci. 16, 201-209 (2013).